Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Moody's Corporation enters its October 20 earnings release with a notable shift in sentiment: short sellers have been quietly adding exposure over the past month, analysts have been cutting targets ahead of the print, and options positioning has edged toward the defensive side, all as the stock trades roughly 16% below the mean Street target.
The positioning picture is worth unpacking. Short interest in MCO has climbed 17% over the past month to 1.57% of the free float, a low absolute level but a meaningful directional shift. The week-on-week pace has picked up too, with shorts adding 11% in the last five days to bring the total to around 2.8 million shares. That said, the borrow market itself remains frictionless. Availability is enormous, with roughly 97.9 million shares available to lend against fewer than 2.8 million shorted, and borrowing costs have actually fallen almost 20% on the week to 0.45%. The ORTEX short score sits at 32.6, placing MCO in a middling 58th percentile on short scoring, well below any squeeze or conviction threshold. Options carry a mild defensive lean: the put/call ratio is at 1.06, a touch above its 20-day average of 1.01, but the z-score of 0.75 is unremarkable. The story here is one of modest and methodical short-side interest building into a known catalyst, not a crowded or aggressive short.
The Street heading into the print reflects a similar tension. Multiple bellwether firms have trimmed targets in the past week. JP Morgan's Andrew Steinerman lowered his target from $570 to $555 on October 14 while keeping his Overweight rating. BMO Capital cut from $515 to $490 on October 13, maintaining Market Perform. Morgan Stanley lowered to $470 from $512 on October 7, holding Equal-Weight. The direction of travel is clear: analysts still broadly positive on the name are becoming less so on valuation. The mean target of $555 implies roughly 20% upside from the current $464, but that gap has been narrowing as targets come down. Factor scores reinforce the mixed picture. EPS surprise ranks in the 82nd percentile, meaning Moody's has a strong track record of beating estimates. But forward earnings momentum is weak, with the 12-month forward EPS year-on-year growth score in just the 27th percentile. The PE multiple sits near 25 times trailing earnings, and EV/EBITDA at around 18 times has been drifting lower over the past 30 days. The bull case rests on credit issuance strength and Moody's Investors Service revenue outperformance. The bear case points to potential credit cycle deceleration and sluggish growth in the Analytics segment.
One institutional data point worth noting is the Wikipedia-derived attention signal from the ORTEX alt data layer. Retail and public attention to Moody's has spiked to a z-score of 3.14 relative to the prior 90 days, as of September 25. That is a high reading. It likely reflects pre-earnings interest rather than anything fundamental, but it does suggest the upcoming print is drawing more scrutiny than usual. There are no measured leading indicators in the alt data for MCO, so this cannot be read as a revenue signal.
Ownership is dominated by long-term anchors unlikely to shift around a quarterly print. Berkshire Hathaway holds 14.2% of shares, unchanged in the most recent filing period. TCI Fund Management holds 8.3%, also unchanged. There is no 13D activist on the register. The Vanguard Group's Schedule 13G/A filed in March shows a zero position, reflecting a restructuring of how that entity reports rather than a fundamental exit, with Vanguard Capital Management separately disclosing a 6.41% stake. The insider picture is quiet in terms of conviction signals. CEO Robert Fauber's October 1 transactions were all conducted under a pre-arranged 10b5-1 plan, comprising option exercises and paired open-market sales. Net insider activity over the past 90 days shows a small negative, around 3,857 shares net sold and roughly $1.9 million in net value terms, but the 10b5-1 context strips most of the signal from those numbers.
One index note on the periphery: ORTEX puts a 37% probability on Moody's joining the CRSP US Mid cap index at the December 2026 Quarterly Review. The stock is currently 7.2% above the entry price line at $430.47. If that addition were confirmed, index trackers would need to buy an estimated $717 million of stock, equivalent to roughly 1.9 days of normal volume. That is a December story, not this week's. The rank date is December 4, with any announcement on December 7.
Earnings history for MCO over the most recent two quarters both show negative day-one reactions: the July 2026 print moved down 3.8% on the day and the prior quarter fell 3.1%. The five-day reactions were also negative, down 1.5% and 4.2% respectively. The pattern is a stock that has been punished even after reporting, which adds context to why analysts are cautious rather than aggressive going into October 20. What to watch next is whether the Moody's Investors Service revenue line and any commentary on credit issuance trends for the remainder of 2026 shifts the target-trimming into something more fundamental.
See the live data behind this article on ORTEX.
Open MCO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
